James H Kulp is a notable inventor based in West Chester, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of actinic keratosis. With a total of 7 patents to his name, Kulp's work focuses on improving patient care through innovative dosing regimens and formulations.

Latest Patents

Kulp's latest patents include a 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod. These patents describe pharmaceutical formulations and methods for the topical or transdermal delivery of imiquimod, aimed at providing effective treatment with shorter therapy durations compared to the commercially available Aldara® 5% imiquimod cream. The formulations are designed to deliver an efficacious dose of imiquimod while maintaining an acceptable safety profile, making the treatment more convenient for patients.

Career Highlights

Throughout his career, Kulp has worked with various companies, including Medicis Pharmaceutical Corporation. His experience in the pharmaceutical industry has allowed him to develop innovative solutions that address the needs of patients suffering from actinic keratosis.

Collaborations

Kulp has collaborated with notable professionals in the field, including Michael T Nordsiek and Sharon F Levy. These collaborations have contributed to the advancement of his research and the development of effective treatment options.

Conclusion

James H Kulp's contributions to the treatment of actinic keratosis through his innovative patents highlight his commitment to improving patient outcomes. His work continues to influence the pharmaceutical industry and offers hope for more effective treatment options.

This text is generated by artificial intelligence and may not be accurate.